STOK vs TFX: fair value comparison
Stoke Therapeutics, Inc. and Teleflex Incorporated · Updated 2026-10-19
STOK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, STOK currently ranks higher by quality score.
| STOK | TFX | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $24.17 | $126.11 |
| 12-month range | $22.37–$38.35 | $100.34–$142.05 |
| Rank by discount to fair value | — | #102 of 108 Healthcare |
| Rank by quality score | #107 of 301 Healthcare | #108 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: STOK fair value analysis · TFX fair value analysis